New research indicates that people who come off new GLP-1 drugs like semaglutide or tirzepatide may regain lost weight far faster than those who halt traditional lifestyle plans.
Published data in a leading health publication demonstrates that while obese people often shed substantial amounts of their total mass while undergoing treatment, the mass returns at an average rate of nearly a kilo each month once they quit.
"People purchasing such medications must be informed of the potential of fast rebound weight gain when the medication concludes," stated expert Dr. Susan Jebb.
Such speed of regain implies a return to pre-treatment weight in about a year and a half.
Analyzing Treatments
The research, which reviewed dozens of trials involving thousands of participants, contrasted the effects of the injectable medications with other pills.
The team note that people who lose weight through dieting generally experience a slower weight regain—around 0.1 kg a month—after stopping.
The Reason for the Quick Regain
Experts believe the way of the drugs accounts for the accelerated regain.
The injections imitate a body's own chemical called GLP-1, which moderates feelings of fullness.
"Long-term administration of the hormone concentrations several times higher than the body's typical production might result in the body to generate a reduced amount of its endogenous hormone, and could lessen responsiveness to its actions," explained Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this medication results in hunger is uncontrolled, making binge eating a significant risk."
An Ongoing Issue?
Medical guidelines suggest the jabs for people with weight-linked medical conditions, alongside prescribed diet and exercise modifications.
Many experts argue that, given the likelihood of relapse, the therapy is often long-term.
This opinion is reinforced by drug manufacturers, who say that the results "underscore the long-term nature of excess weight," similar to managing conditions like hypertension.
User Accounts
Individuals who have discontinued the medication explain a sudden resurgence of hunger.
"It was like a switch flipping and I was suddenly ravenous," described one woman.
The struggle is exacerbated if patients have not established sustainable dietary or behavioural changes during treatment.
Widespread Interest
Figures show that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with interest continuing to grow.
- Adoption is more common among women than men.
- The middle-aged age group shows the greatest usage rates.
- A large proportion access the medications through private healthcare rather than public health services.
Ultimately, clinicians caution that while GLP-1 drugs are powerful agents for weight loss, they are not a standalone fix and lasting health benefits relies on integrated behavioural changes.
